Table 3.
Incidence of RSVH in preterms and other high-risk groups
| RSVH children | Non-RSVH children | Incidence of RSVH (95% CI) | ||
|---|---|---|---|---|
| Gestational age at birth | < 29 weeks | 277 | 1891 | 12.8%* (11.4–14.3%) |
| < 32 weeks | 839 | 5453 | 13.3%* (12.5–14.2%) | |
| 29–32 weeks | 562 | 6329 | 8.2%* (7.5–8.8%) | |
| < 36 weeks | 1710 | 26,279 | 6.1%* (5.8–6.4%) | |
| ≤ 36 weeks | 2320 | 42,319 | 5.2%* (5.0–5.4%) | |
| 33–35 weeks | 871 | 18,059 | 4.6%* (4.3–4.9%) | |
| > 36 weeks | 11,023 | 567,711 | 1.9% (1.9–1.9%) | |
| Comorbidities | CHD and PH | 534 | 4576 | 10.5%‡ (9.6–11.3%) |
| CLD and BPD | 228 | 1803 | 11.2%‡ (9.9–12.7%) | |
| Down syndrome | 87 | 500 | 14.8%‡ (12.0–18.0%) | |
| Turner syndrome | 1 | 42 | 2.3% (0.1–12.3%) | |
| Cystic fibrosis | 30 | 209 | 12.6%‡ (8.6–17.4%) | |
| Cerebral palsy | 61 | 332 | 15.5%‡ (12.1–19.5%) | |
| Neuromuscular disorders | 8 | 39 | 17.0%‡ (7.6–30.8%) | |
| Other† | 2 | 41 | 4.7% (0.6–15.8%) | |
| No comorbidities | 12,411 | 602,866 | 2.0% (2.0–2.1%) | |
BPD bronchopulmonary dysplasia, CHD congenital heart disease, CI confidence interval, CLD congenital lung disease, PH pulmonary hypertension, RSVH respiratory syncytial virus hospitalisation
*p < 0.0001 vs. term (> 36 weeks’ gestational age); ‡p < 0.0001 vs. no comorbidities; †congenital immunodeficiency disorders and osteogenesis imperfecta